Radioembolizace plus chemoterapie pro první linii léčby lokálně pokročilého intrahepatálního cholangiokarcinomu

• The authors of this phase II clinical trial evaluated concomitant first-line chemotherapy (cisplatin and gemcitabine) combined with selective internal radiotherapy (SIRT) using glass microspheres in 41 patients with unresectable intrahepatic cholangiocarcinoma with no prior chemotherapy or intra-arterial therapy. The response rate according to RECIST criteria was 39%, and 22% of patients were downstaged to surgical intervention, with 20% achieving R0 resection. The median relapse-free survival was not reached among patients who underwent resection. Among all patients, after a median follow-up of 36 months, median progression-free survival was 14 months and median overall survival was 22 months.

• This approach showed promising findings for downstaging among patients with unresectable intrahepatic cholangiocarcinoma, and a phase III trial is ongoing to investigate further.

více zde